Novo Partners With Boehringer Ingelheim On Drug Discovery

“is the target that we've discovered because we have this differential data. that leads to a novel target with strong human genetic evidence that others aren't working on. And that's where AI, I was a skeptic a few years ago, I am the opposite of a skeptic now.”

“amounts of proprietary data using agents to sort through it and find. out, it flag for you what is novel and what can make a difference and what is a new drug target that others aren't working on. That's where AI is particularly useful. And I know to date you have 24 different projects.”

“couple dozen projects like like we've described around the globe each with thousands of individuals all with very rich multi-iomic data. And then again, we've harmonized all of the world's publicly available data, put it all in one platform so it can all be queried together.”

“of AI have allowed us to find a number of targets that This is what we're looking for a combination of extremely strong human genetic evidence and they're they're different They're not the targets that everyone else is working on because they”

“They found the human genetic evidence in the UK Biobank, right? The large data set that everyone looks at. We look for targets that have that combination of very strong human genetic.”

“look for targets that have that combination of very strong human genetic. evidence and others don't know about that evidence because we have differentiated human variation that others don't know about that allows us to find these novel targets.”

“We have access to the world's genetic diversity. That has allowed us to make a novel finding. We can develop a drug targeting area of significant unmet medical need.”

“able to find more targets than we can ever work on ourselves. So we've taken several of those programs and we've launched them internally as our own pipeline We've also put several of them into the hands of world-class companies like Novo and”